April 11, 2026 11:15 AM - 11:45 AM PT

In-Person & Virtual

Overview

Historically, systemic therapy for advanced pancreatic ductal adenocarcinoma (PDAC) has been limited mainly to multiagent cytotoxic chemotherapy, with most efforts to develop other approaches failing even for targets that have been established in other forms of cancer. In recent years, however, the discovery of effective inhibitors of mutated RAS offers the potential to transform the standard of care in PDAC, which is associated with mutations in the RAS pathway in most cases.

This live educational symposium is designed to bring clinicians up to speed on the emerging approaches to target KRAS in advanced PDAC, framed in the discussion of challenging case scenarios where novel treatments could fit.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Interpret efficacy and safety data from recent and ongoing clinical trials of KRAS-targeted therapies for advanced PDAC
• Apply emerging clinical evidence, molecular profiling results, and patient-specific factors to guide the selection and sequencing of targeted therapies in advanced PDAC

Target Audience

This educational activity is directed toward oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care professionals involved in the diagnosis and treatment of pancreatic cancer.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medical Oncologists (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn 0.5 MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Acknowledgement of Educational Grant Support

This activity is supported by an educational grant from Revolution Medicines.